To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Axel H. Leimer was born in Frankfurt, Germany and has studied biochemistry at the University of Colorado and Baylor College of Medicine. He has worked on dual action protease inhibitors and is co-inventor of a series of serine and cysteine inhibitors. He described several interleukin-converting enzyme ("ICE") inhibitors and coauthored a study on alternative processing of ICE through proteinease 3. His work also includes combining pharmacophores of Bradykinin B1 and B2 anatagonists with that of a protease inhibitor for the treatment of inflammatory diseases. His work also included the identification of a small molecular weight glycosylated serum ferritin secreted from the heart, showing that the heart acts as an endocrine organ.
Leimer has been managing director of Source Precision Medicine Europe and Executive Board Member and CBO/COO of Vectron Pharmaceuticals AG, Marburg, Germany. He is currently managing a consulting business and is Investment Advisor of Future Capital AG. Previous employment includes Hoechst AG, Frankfurt, Germany, Rocky Mountain BankCard, Cortech Inc., Denver, Colorado and Vertex Pharmaceuticals, Cambridge, Massachusetts.
Leimer is co-founder of Kinaxo GmbH, Munich.
Leimer has served from 2001 through 2007 as a bishop in the Church of Jesus Christ of Latter-Day Saints in Frankfurt-Höchst, Germany and was called as stake president of the Stakein June 2007.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Axel_Leimer". A list of authors is available in Wikipedia.|